Status:
COMPLETED
Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Lead Sponsor:
Telik
Conditions:
Non Small Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine if TLK286(Telcyta) is more effective than gefitinib (Iressa) in the treatment of non-small cell lung cancer.
Eligibility Criteria
Inclusion
- Clinical diagnosis of non-small cell lung cancer
- Non-small cell lung cancer that is not curable with surgery, radiation, or combined modality chemoradiation
- Failed two prior chemotherapy regimens which must have included platinum
- Measurable disease
Exclusion
- Treatment with more than two prior chemotherapy regimens
- History of bone marrow transplantation or stem cell support
- Pregnant or lactating women
- Known history of prior gefitinib therapy
- Known history of prior TLK286 therapy
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
May 1 2005
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT00080340
End Date
May 1 2005
Last Update
January 15 2008
Active Locations (338)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB CCC Clinical Studies Unit
Birmingham, Alabama, United States, 35233-2115
2
Department of Veterans Affairs Medical Center
Birmingham, Alabama, United States, 35233
3
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233
4
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294